The increasing value of plant-made proteins

Abstract

The production of high-value proteins in plants is maturing, as shown by the recent approval of innovative products and the latest studies that showcase plant-based production systems using technologies and approaches that are well established in other fields. These include host cell engineering, medium optimization, scalable unit operations for downstream processing (DSP), bioprocess optimization and detailed cost analysis. Product-specific benefits of plant-based systems have also been exploited, including bioencapsulation and the mucosal delivery of minimally processed topical and oral products with a lower entry barrier than pharmaceuticals for injection. Success stories spearheaded by the FDA approval of Elelyso developed by Protalix have revitalized the field and further interest has been fueled by the production of experimental Ebola treatments in plants.

Identifikasi famili gen putatif penyandi protease inhibitor dengan pendekatan in silico komparatif pada genom Hevea brasiliensis Muell. Arg (Identification of putative gene family encoding protease inhibitors by in silico comparative analysis in Hevea brasiliensis Muell. Arg genome)

“…Protease inhibitor disinyalir sebagai produk yang memiliki nilai ekonomi yang tinggi dalam sektor pertanian dan kesehatan dikarenakan memiliki kemampuan anti-mikroba dan anti-virus (Bijina et al, 2011;Islamov et al, 2012;Sack et al, 2015). PI bekerja dengan cara menghambat, menghidrolisis, mengubah atau menonaktifkan protease yang diekskresikan oleh patogen sehingga menjadi avirulen (Ryan, 1990).…”

Vacuolar deposition of recombinant proteins in plant vegetative organs as a strategy to increase yields

“…Foreign proteins can be produced by using either transient expression in leaves or transgenic expression systems in whole plants or plant cell culture. 1 Both transient and stable systems are fully scalable and several large scale manufacture facilities are available, including those that satisfy good manufacturing practice (GMP). 1 Recombinant protein yields are widely variable and depend on numerous factors such as plant species, promoter, enhancers, incorporation of intron sequences, mRNA stability, 5 0 and 3 0 untranslated regions, codon usage, protein folding and stability, etc.…”

“…1 Both transient and stable systems are fully scalable and several large scale manufacture facilities are available, including those that satisfy good manufacturing practice (GMP). 1 Recombinant protein yields are widely variable and depend on numerous factors such as plant species, promoter, enhancers, incorporation of intron sequences, mRNA stability, 5 0 and 3 0 untranslated regions, codon usage, protein folding and stability, etc. 2,3 Different technologies have been developed to increase transcription efficiency, mRNA stability and translation effectiveness and to improve protein folding and stability.…”

“…1 Plant based platforms have several advantages such as low upstream costs, no risk of contamination with human or animal pathogens, absence of bacterial toxins, easy and rapidly scale up with low investment cost, availability of different technology to reduce downstream process cost, etc. Foreign proteins can be produced by using either transient expression in leaves or transgenic expression systems in whole plants or plant cell culture.…”

Purification, characterization, and bioassay of putative protease inhibitors from Hevea brasiliensis latex

“…The increased use in agriculture sector as an antimicrobial agent has positioned plant protease inhibitors as an important product (Bijina et al, 2011;Islamov et al, 2012;Sack et al, 2015). Isolation and characterization of protease inhibitors from various plant species have been carried out using affinity column chromatography (Bijina et al, 2011;Popovic et al, 2013;Al-Assadi, 2013, Bunyatang et al, 2013Chaudhary et al, 2008;Sabotič et al, 2012).…”